Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024-Reference-Cited by-同舟云学术

Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024

Published:2024-09-12 Issue:36 Volume:73 Page:793-798
ISSN:0149-2195
Container-title:MMWR. Morbidity and Mortality Weekly Report
language:
Short-container-title:MMWR Morb. Mortal. Wkly. Rep.

Author:

Kobayashi Miwako,Leidner Andrew J.,Gierke Ryan,Farrar Jennifer L.,Morgan Rebecca L.,Campos-Outcalt Doug,Schechter Robert,Poehling Katherine A.,Long Sarah S.,Loehr Jamie,Cohen Adam L.

Publisher

Centers for Disease Control MMWR Office

Reference19 articles.

1. CDC. Active Bacterial Core surveillance (ABCs): surveillance reports. Atlanta, GA: U.S Department of Health and Human Services; 2024. https://www.cdc.gov/abcs/reports/index.html

2. Pneumococcal vaccine for adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023.;Kobayashi;MMWR Recomm Rep,2023

3. Center for Biologics Evaluation and Research. CAPVAXIVE. Silver Spring, MD: Food and Drug Administration; 2024. https://www.fda.gov/vaccines-blood-biologics/capvaxive

4. Kobayashi M. Evidence to recommendations framework: PCV20 use among adults who previously received PCV13 [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 19, 2022. https://stacks.cdc.gov/view/cdc/122357

5. Orell L, Massay S, Steinberg J, ISPPD-13: increase in invasive pneumococcal disease due to Streptococcus pneumoniae serotype 4—Alaska, 2013–2022. Geneva, Switzerland: International Society of Pneumonia and Pneumococcal Diseases; 2024. https://info.kenes.com/Flip/ISPPD24_ISPPD24/